Risvutatug rezetecan
Based on 1 Customer Validation
Risvutatug rezetecan (HS-20093; GSK5764227) is a B7-H3-targeting antibody-drug conjugate (ADC). Risvutatug rezetecan binds to B7-H3 on tumor cells and delivers a topoisomerase I inhibitor payload via a tumor microenvironment-responsive cleavable linker. Risvutatug rezetecan is applicable for the research of extensive-stage small cell lung cancer and non-small cell lung cancer.
For research use only. We do not sell to patients.
- Purity: 99.70%
- CAS No.: 3042849-33-9
-
Storage:
-80°C, protect from light
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Chemical Information
-
CAS No. 3042849-33-9
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Risvutatug rezetecan]
-
Synonyms
HS-20093; GSK5764227
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Risvutatug rezetecan Related Classifications
Cat. No.: HY-185279
Powered by Bioz
- Risvutatug rezetecan
- 3042849-33-9
- HS-20093
- GSK5764227
- HS20093
- HS 20093
- GSK5764227
- GSK 5764227
- GSK-5764227
- Antibody-Drug Conjugates (ADCs)
- CD276/B7-H3
- cleavable linker
- lung cancer
- preclinical models
- pharmacokinetic properties
- antibody-drug conjugate
- tumor cells
- antitumor activity
- tumor microenvironment
- topoisomerase I inhibitor
- B7-H3
- Inhibitor
- inhibitor
- inhibit